-
- Arash Safavi
- Department of Surgery, University of Arizona, Tucson, AZ 85724-5131, USA
-
- Aparna Vijayasekaran
- Department of Surgery, University of Arizona, Tucson, AZ 85724-5131, USA
-
- Marlon A. Guerrero
- Department of Surgery, University of Arizona, Tucson, AZ 85724-5131, USA
説明
<jats:p>The vast majority of patients with differentiated thyroid cancer (DTC) are treated successfully with surgery and radioactive iodine ablation, yet the treatment of<jats:italic>advanced</jats:italic>cases is frustrating and largely ineffective. Systemic treatment with conventional cytotoxic chemotherapy is basically ineffective in most patients with advanced DTC. However, a better understanding of the genetics and biologic basis of thyroid cancers has generated opportunities for innovative therapeutic modalities, resulting in several clinical trials. We aim to delineate the latest knowledge regarding the biologic characteristics of DTC and to describe the available data related to novel targeted therapies that have demonstrated clinical effectiveness.</jats:p>
収録刊行物
-
- Journal of Thyroid Research
-
Journal of Thyroid Research 2012 1-8, 2012
Hindawi Limited
